These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Docetaxel: new indication. First-line treatment of non small-cell lung cancer: no advance. Prescrire Int; 2005 Feb; 14(75):16-8. PubMed ID: 15751170 [TBL] [Abstract][Full Text] [Related]
44. Enhancement of the potentiation of radiotherapy by platinum drugs in a mouse tumor. Douple EB; Richmond RC Int J Radiat Oncol Biol Phys; 1982; 8(3-4):501-3. PubMed ID: 7201991 [TBL] [Abstract][Full Text] [Related]
45. Chemoradiation for locally advanced, unresectable NSCLC. New standard of care, emerging strategies. Gordon GS; Vokes EE Oncology (Williston Park); 1999 Aug; 13(8):1075-88; discussion 1088, 1091-4. PubMed ID: 10499243 [TBL] [Abstract][Full Text] [Related]
46. [Treatment of unresectable non-small-cell lung cancer]. Ueoka H Gan To Kagaku Ryoho; 2000 Mar; 27(3):356-61. PubMed ID: 10740628 [TBL] [Abstract][Full Text] [Related]
47. Integration of new chemotherapeutic agents into chemoradiotherapy for stage III non--small cell lung cancer: focus on docetaxel. Gandara DR; Lara PN; Goldberg Z; Lau DH Semin Oncol; 2001 Jun; 28(3 Suppl 9):26-32. PubMed ID: 11441412 [TBL] [Abstract][Full Text] [Related]
48. The role of radiotherapy in the management of cancer--an overview. Tobias JS Ann Acad Med Singap; 1996 May; 25(3):371-9. PubMed ID: 8876904 [TBL] [Abstract][Full Text] [Related]
54. Concurrent chemoradiation for cervical cancer: what should we do next? Toita T Int J Clin Oncol; 2006 Aug; 11(4):253-5. PubMed ID: 16937297 [No Abstract] [Full Text] [Related]
55. [Changes in radiation lesions using platinum derivatives. Biological bases and clinical experience]. Calvo FA; Ortiz de Urbina D; Abuchaibe O; Aristu J; Santos M Rev Esp Fisiol; 1989; 45 Suppl():315-21. PubMed ID: 2701768 [TBL] [Abstract][Full Text] [Related]
56. [The guidelines for diagnostics and treatment of cervical cancer]. Inciūra A; Juozaityte E Medicina (Kaunas); 2004; 40(4):394-403. PubMed ID: 15111756 [TBL] [Abstract][Full Text] [Related]
57. Preliminary results of combined therapy with topotecan and carboplatin in advanced non-small-cell lung cancer. Pujol JL; von Pawel J; Tumolo S; Martoni A; Hearn S; Fields SZ; Ross G Oncology; 2001; 61 Suppl 1():47-54. PubMed ID: 11598415 [TBL] [Abstract][Full Text] [Related]
58. Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb nonsmall cell lung cancer: a meta-analysis. Pignon JP; Stewart LA Cancer; 1996 Jun; 77(11):2413-4. PubMed ID: 8635115 [No Abstract] [Full Text] [Related]
59. Phase I study of weekly cisplatin, vinorelbine, and concurrent thoracic radiation therapy in patients with locally advanced non-small-cell lung cancer. Kobayashi M; Matsui K; Hirashima T; Nitta T; Sasada S; Tada T; Minakuchi K; Furukawa M; Ogata Y; Kawase I Int J Clin Oncol; 2006 Aug; 11(4):314-9. PubMed ID: 16937306 [TBL] [Abstract][Full Text] [Related]
60. Radiosensitizing effect of cisplatin in prostate cancer cell lines. Geldof AA; Slotman BJ Cancer Lett; 1996 Mar; 101(2):233-9. PubMed ID: 8620475 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]